OKYO Pharma enrolls first patients in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain
OKYO•OKYO Pharma enrolled the first patients in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain; no clinical results were presented.
1. Trial enrollment begins
OKYO Pharma enrolled the first patients in its Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic corneal pain. The study is intended to generate evidence for a potential first-in-class, disease-modifying treatment for a condition with no FDA-approved therapies.
